MyFinsight
Home
Blog
About
Filspari
$13,567K
(106.25%↑ Y/Y)
Kyprolis
$7,044K
(-19.98%↓ Y/Y)
Royalty Intangible
Other
$4,269K
(-21.42%↓ Y/Y)
Intangible Ohtuvayre
$4,144K
Rylaze
$3,201K
(11.77%↑ Y/Y)
Capvaxive
$2,316K
Teriparatide Injection
$1,470K
(-36.03%↓ Y/Y)
Vaxneuvance
$1,351K
(-48.88%↓ Y/Y)
QARZIBA
$6,150K
(4.50%↑ Y/Y)
Financial Ohtuvayre
Inventors
$3,294K
Financial Royalty Other
$1,226K
(186.45%↑ Y/Y)
Intangible Royalty Assets
$37,362K
(24.19%↑ Y/Y)
Financial Royalty Assets
$10,670K
(69.02%↑ Y/Y)
Contract And Revenue
Income Other
$5,000K
(391.64%↑ Y/Y)
Contract Revenue
$2,683K
Royalty
$48,032K
(31.97%↑ Y/Y)
Material Sales Captisol
$7,978K
(-3.73%↓ Y/Y)
Contract Revenue And
Other Income
$7,683K
(161.06%↑ Y/Y)
Loss (gain) from
change in fair value of...
$35,727K
Gain (loss) from
short-term investments
$11,754K
(1151.76%↑ Y/Y)
Interest income
$7,298K
(350.22%↑ Y/Y)
Other non-operating
expense, net
$2,682K
(95.48%↑ Y/Y)
Total revenues and
income
$63,693K
(33.73%↑ Y/Y)
Total non-operating
income (expenses), net
$55,713K
(1904.79%↑ Y/Y)
Operating income (gain)
$8,591K
(1.74%↑ Y/Y)
Interest expense
$1,748K
(51.60%↑ Y/Y)
Total operating costs
and expenses
$55,102K
(40.63%↑ Y/Y)
Income (gain) before
income taxes
$64,304K
(472.97%↑ Y/Y)
General and
administrative
$29,123K
(44.35%↑ Y/Y)
Research and development
$14,668K
(123.36%↑ Y/Y)
Amortization of intangibles
$8,097K
(-1.95%↓ Y/Y)
Cost of captisol
$3,214K
(10.56%↑ Y/Y)
Net income (gain)
$48,508K
(900.78%↑ Y/Y)
Income tax (expense)
benefit
$15,796K
(147.74%↑ Y/Y)
Back
Back
Income Statement
LIGAND PHARMACEUTICALS INC (LGNDZ)
LIGAND PHARMACEUTICALS INC (LGNDZ)
source: myfinsight.com